advanced search

RESPIRATORY

ADVANCING PHARMACEUTICAL CONTACT APPLICATIONS WITH PEEK: MEETING INCREASING DEMANDS
INDUSTRIALISATION
Marcus Jarman-Smith
Victrex
ADVANCING PHARMACEUTICAL CONTACT APPLICATIONS WITH PEEK: MEETING INCREASING DEMANDS
Marcus Jarman-Smith and Yann Tréguier, discuss the myriad benefits that Victrex’s pharmaceutical-grade PEEK can offer to the drug delivery sector as a material of construction due to its versatile material properties.
HIGH-DOSE DELIVERY PLATFORM FOR CRYSTALLINE DPIs
PULMONARY
Dr Susana Saldanha
Hovione
HIGH-DOSE DELIVERY PLATFORM FOR CRYSTALLINE DPIs
Susana Saldanha, Lídia Santos and Rui Churro, discuss the benefits of crystalline formulations for inhalation devices.
ARCUS<sup>®</sup>: A COMMERCIALISED TECHNOLOGY ENABLING HIGH-DOSE, HIGHLY RESPIRABLE POWDERS
INDUSTRIALISATION
Dr Alan Watts
Catalent Pharma Solutions
ARCUS®: A COMMERCIALISED TECHNOLOGY ENABLING HIGH-DOSE, HIGHLY RESPIRABLE POWDERS
Alan Watts and Michael Tauber, discuss the requirements and benefits of using spray-dried powders for inhalation, and how ARCUS, used for the successfully commercialised Inbrija® dry powder inhaler, is a prime example of this technology in action.
ADVANCING OINDP CLINICAL TRIALS WITH SPEED AND EFFICIENCY: STRATEGIES FOR SUCCESS
RESPIRATORY
Gemma Budd
Aptar Pharma
ADVANCING OINDP CLINICAL TRIALS WITH SPEED AND EFFICIENCY: STRATEGIES FOR SUCCESS
Gemma Budd and Julie Suman, consider the key issues that preclinical and clinical trials for orally inhaled and nasal drug products must address within the context of the information that regulators are looking for, providing insight, strategies and advice for both novel and generic products in this sector.
BETTER IN VIVO PREDICTION FROM OINDP TESTING: A GOAL WORTH PURSUING?
PULMONARY
Matthew Fenn
Copley Scientific
BETTER IN VIVO PREDICTION FROM OINDP TESTING: A GOAL WORTH PURSUING?
Matthew Fenn and Clair Brooks, consider the motivation for adopting more clinically representative test set-ups in orally inhaled and nasal drug product development and, more specifically, for the demonstration of bioequivalence, as well as the practicalities of doing so and the tools available to support such efforts.
Interview with Sandy Munro, Vectura
INTERVIEW
Dr Sandy Munro
Vectura
Interview with Sandy Munro, Vectura
In this exclusive interview with ONdrugDelivery’s Guy Furness, Sandy Munro, PhD, of Vectura discusses his extensive career, focused on respiratory drug delivery. He shares his insights into current trends within the industry, including the growth of biologics, systemic delivery via inhalation, the potential of mesh nebulisers and connectivity in clinical trials. 
DEEP BREATHS, DEEP DIVES: THE NEW eFLOW INTEGRATED NEBULISER
PULMONARY
Gesa Braunlich
PARI
DEEP BREATHS, DEEP DIVES: THE NEW eFLOW INTEGRATED NEBULISER
Gesa Bräunlich and Michael Hahn discuss PARI’s new eFlow integrated nebuliser.
THE EVOLUTION OF PULMONARY & NASAL DRUG DELIVERY
RESPIRATORY
Mike Needham
Kindeva Drug Delivery
THE EVOLUTION OF PULMONARY & NASAL DRUG DELIVERY
Mike Needham takes a look at the history of, and progress in, inhalation technology and discusses what might lie ahead.
BUBBLE-WRAPPED REMEDIES: HOW LIPID-ENCASED THERAPEUTICS COULD TRANSFORM INHALATION
EXPERT VIEW
Dr Ethan Miller
BUBBLE-WRAPPED REMEDIES: HOW LIPID-ENCASED THERAPEUTICS COULD TRANSFORM INHALATION
Ethan Miller and Heather Jameson shed light on some of the intricacies that lipid-encapsulated therapeutics bring to the realm of inhalation therapies, and some considerations on how the type of inhalation device selected may help to mitigate issues around formulation stability and efficient delivery to target cells.
HOW TO CHOOSE THE RIGHT INTRANASAL VACCINE DEVICE
EXPERT VIEW
Dr Nia Stevens
HOW TO CHOOSE THE RIGHT INTRANASAL VACCINE DEVICE
Nia Stevens, discusses the potential benefits of developing vaccines for intranasal administration with a suitable drug delivery device, as well as the challenges associated with this delivery route.
THE PATH TO NASAL DRUG PRODUCT COMMERCIALISATION
EXPERT VIEW
Eric Kaneps
THE PATH TO NASAL DRUG PRODUCT COMMERCIALISATION
Eric Kaneps discusses the benefits of nasal drug delivery compared with other administration routes – and the challenges in R&D and clinical manufacturing.
EXPLORING THE POTENTIAL OF NEBULISED BIOLOGICS
EXPERT VIEW
Carolina Dantas
EXPLORING THE POTENTIAL OF NEBULISED BIOLOGICS
Carolina Dantas and Ulf Krueger consider the challenges when it comes to the successful delivery of inhaled biological drugs.
CUSTOMISABLE NEBULISER PLATFORM TO MONITOR ADHERENCE
CONNECTIVITY
Edgar Hernan Cuevas Brun
HCmed Innovations
CUSTOMISABLE NEBULISER PLATFORM TO MONITOR ADHERENCE
Edgar Hernan Cuevas Brun and Yuan-Ming Hsu discuss the value that customisable nebuliser platforms bring to patient adherence.
IMPROVING MEDICATION ADHERENCE AND CLINICAL OUTCOMES THROUGH CONNECTED DRUG DELIVERY DEVICES
CONNECTIVITY
Joachim Koerner
Aptar Digital Health
IMPROVING MEDICATION ADHERENCE AND CLINICAL OUTCOMES THROUGH CONNECTED DRUG DELIVERY DEVICES
Joachim Koerner and Marcus Bates discuss the challenge that medication non-adherence presents to the healthcare sector, and the potential value of connected digital health solutions as a way of overcoming this challenge.
SMART SCALING FOR SUCCESSFUL CAPSULE-BASED DRY POWDER INHALER FILLING USING DRUM TECHNOLOGIES
PULMONARY
Carolyn Berg
Catalent Pharma Solutions
SMART SCALING FOR SUCCESSFUL CAPSULE-BASED DRY POWDER INHALER FILLING USING DRUM TECHNOLOGIES
Carolyn Berg, William Chin and Patrick Goncalves discuss the considerations for filling capsules for dry powder inhalers across the various stages of clinical trials and commercialisation, and how to tackle the challenges of scaling up filling processes.
SPRAY DELIVERY: TARGETING PATIENT NEEDS AND EXPECTATIONS WITH PRECISION
PULMONARY
Gladys Corrons-Bouis
Eveon
SPRAY DELIVERY: TARGETING PATIENT NEEDS AND EXPECTATIONS WITH PRECISION
Gladys Corrons-Bouis and Cyril Le Loc’h discuss the use of spray delivery for precise targeting of patient medication.
FUTURE-PROOFING pMDI DESIGN TO FIT A CHANGING MARKET
EXPERT VIEW
Ross Errington
FUTURE-PROOFING pMDI DESIGN TO FIT A CHANGING MARKET
Ross Errington explores how pharmaceutical companies can evolve their pMDI drug products to make them fit for the future considering the several recent regulatory changes that are transforming the landscape of inhalation drugs.
CHALLENGES BESIDES DRUG TARGETING – REGULATORY HURDLES FOR MULTIDOSE NASAL SPRAYS
NASAL
Dr Marie-Christine Klein
URSATEC
CHALLENGES BESIDES DRUG TARGETING – REGULATORY HURDLES FOR MULTIDOSE NASAL SPRAYS
Marie-Christine Klein,  Andreas Bilstein and Rouven Kraus, discuss recent regulatory changes affecting drug-device combination products, using the example of a multidose nasal spray.
THE END OF THE ROAD FOR pMDIs?
EXPERT VIEW
Finn Heraghty
THE END OF THE ROAD FOR pMDIs?
Finn Heraghty and Heather Jameson explore the extent to which the healthcare needs of a population could be covered by the combined use of soft mist inhalers and dry powder inhalers, and discuss the factors that will impact the continued importance of pressurised metered dose inhalers going forward.
BENEFITS OF INNOVATIVE COMPRESSED GAS-POWERED INTRANASAL DRUG DELIVERY DEVICES
PULMONARY
Albie Lavin
Picocyl
BENEFITS OF INNOVATIVE COMPRESSED GAS-POWERED INTRANASAL DRUG DELIVERY DEVICES
Albie Lavin discusses the exciting potential of propellant-driven systems for intranasal delivery, and how Picocyl’s Pico-Cylinders provide the ideal mechanism to take advantage of this potential.
TAKING A DRUG TO FIRST-IN-HUMAN TRIALS IN A BESPOKE DEVICE FOR TARGETED INTRANASAL DELIVERY
EXPERT VIEW
Dr Mark Allen
TAKING A DRUG TO FIRST-IN-HUMAN TRIALS IN A BESPOKE DEVICE FOR TARGETED INTRANASAL DELIVERY
Mark Allen, Andrew Fiorini and Shai Assia discuss the need to develop delivery devices early when formulating nasally delivered drugs for systemic and local action, and a method by which the route to clinic can be made easier, faster and cheaper. 
NASAL DRUG DELIVERY: OVERCOMING CHALLENGES WITH A ROBUST PLATFORM STRATEGY
EXPERT VIEW
Dr Richard Johnson
NASAL DRUG DELIVERY: OVERCOMING CHALLENGES WITH A ROBUST PLATFORM STRATEGY
Richard Johnson explores the changing nasal delivery landscape, highlighting challenges in nasal drug formulation and potential methods to overcome them.
UNLOCKING THE POTENTIAL OF INTRANASAL DRUG DELIVERY
NASAL
Allan Houston
Silgan Dispensing
UNLOCKING THE POTENTIAL OF INTRANASAL DRUG DELIVERY
Allan Houston, Marcel Sachs and Heiko Rolland discuss the healthcare potential of intranasal drug delivery systems and the necessary steps for bringing these solutions to market. 
PERFECT TIMING FOR THE AUTOMATION OF OINDP TESTING
PULMONARY
Adam Smith
Copley Scientific
PERFECT TIMING FOR THE AUTOMATION OF OINDP TESTING
Adam Smith and Clair Brooks take a look at the benefits of automation, focusing on the actuation of metered dose inhalers and multidose nasal sprays/aerosols.
Top